Diagnostics solutions startup with a range of products to tackle Chronic Kidney Disease (CKD), diabetes and preeclampsia (a pregnancy complication). Proflo-U measures albumin and creatinine round the clock; Eyera Sense allows for high efficiency processing of fluid samples; while Embargo offers a portfolio of DNA and RNA based diagnostics kits. Bhubaneswar based. ₹3CR raised in this seed round.

BioTech startup which uses nanotechnology to target cancer stem cells while sparing healthy cells, thereby reducing the need for chemotherapy and reducing relapse. The company uses exosome-based drug delivery. Exosomes are small sacs that are naturally released by cells and can carry a variety of molecules. Exosomes can be used to transport drugs to specific cells or tissues. The company will manufacture its products inhouse. Bhubaneswar based. ₹3CR raised in this seed round.

Neuroscience startup which enables greater precision in the diagnosis and treatment planning of neuro-oncological and neuropsychiatric disorders. Provides clinicians an fMRI processing engine and machine-learning models; and a patient care app. In India, now looking at US market entry. $5M raised in this Pre-Series A round, with $925K raised earlier from Pfizer.

Gen-AI driven SaaS to manage healthcare insurance claims. Targeting a global customer base. Claims generation, processing and fraud detection, along with a suite of other solutions for hospitals and insurers. ₹5CR raised in this seed round.

AI agents to reduce administrative tasks faced by healthcare providers in the US, a lot of which continue to be manual processes faced by both the providers as well as their patients. Confido part automates tasks such as appointments, payments and pre and post operative engagement. $3M raised in this seed round.

Allogeneic Cell & Gene Therapy (CGT) startup, developing affordable and quality access to curative cell therapies for patients in India and the rest of the world. Fundraise towards setting up an FDA-standard manufacturing facility and entering Phase I trials. $4.2M raised in this seed round.

Pharma startup developing affordable, novel small-molecule targeted therapies leveraging AI. Therapies target GLP-1 and GIP receptors for Cardio-metabolic (CM) diseases, with an emphasis on diabetes and obesity. Angel round, amount undisclosed.

Healthcare diagnostics startup. Developing a device and AI based software that provides blood sample results in under ten minutes. $700K raised in this round.

AI driven mental health and wellness platform. Targets individuals and corporates who can measure, manage and improve their wellness and engagement. ₹1CR raised in pre-seed funding.

Uses nanorobots in dentistry to solve for tooth decay. Has developed two devices, for use by dentists (B2B) as well as a toothbrush-like device to be available over the counter (B2C). Funds to be used towards a manufacturing facility and aiming at clinical trials in 2025. Raised $1.2M in this seed round at a valuation of $7.1M. Incubated at IISC.